Product/Composition:- | Palonosetron Injection |
---|---|
Strength:- | 0.25 mg/5 mL vial |
Form:- | Injection |
Reference Brands:- | Aloxi(US) Palonosetron(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Palonosetron Injection 0.25 mg/5 mL is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). Approved in both the U.S. and EU, it is particularly effective for patients undergoing highly emetogenic chemotherapy. Available in a single-dose vial for IV administration, it plays a key role in oncology B2B distribution, helping oncology centers manage chemotherapy side effects and improve patient comfort.
Palonosetron Injection 0.25 mg/5 mL is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It is particularly effective for patients undergoing highly emetogenic chemotherapy regimens. Approved in both the U.S. (under the brand name Aloxi) and the EU, Palonosetron is available as a single-dose 0.25 mg/5 mL vial for IV administration. This drug is essential in oncology B2B distribution, helping oncology centers and hospitals manage the side effects of chemotherapy, ensuring better patient outcomes by reducing nausea and vomiting after treatment.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications